Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Cash & Current Investments (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Cash & Current Investments for 5 consecutive years, with $22.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 412.81% to $22.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.3 million through Dec 2025, up 412.81% year-over-year, with the annual reading at $14.3 million for FY2025, N/A changed from the prior year.
  • Cash & Current Investments for Q4 2025 was $22.3 million at Neuphoria Therapeutics, up from $13.7 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $24.0 million in Q2 2022, with the low at $4.3 million in Q4 2024.
  • Average Cash & Current Investments over 4 years is $14.5 million, with a median of $14.0 million recorded in 2025.
  • The sharpest move saw Cash & Current Investments crashed 49.26% in 2023, then soared 412.81% in 2025.
  • Over 4 years, Cash & Current Investments stood at $24.0 million in 2022, then plummeted by 49.26% to $12.2 million in 2023, then plummeted by 64.38% to $4.3 million in 2024, then skyrocketed by 412.81% to $22.3 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $22.3 million, $13.7 million, and $14.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.